Man Group plc Purchases New Shares in Axsome Therapeutics, Inc. $AXSM

Man Group plc acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 2nd quarter, HoldingsChannel reports. The firm acquired 82,526 shares of the company’s stock, valued at approximately $20,200,000.

Several other institutional investors have also recently made changes to their positions in the company. Kemnay Advisory Services Inc. purchased a new position in Axsome Therapeutics during the fourth quarter worth about $31,000. Ameriflex Group Inc. purchased a new stake in Axsome Therapeutics in the 4th quarter valued at about $37,000. Hollencrest Capital Management increased its stake in Axsome Therapeutics by 400.0% in the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after buying an additional 160 shares during the last quarter. ABS Investment Management LLC bought a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $171,339,000. Finally, Silvant Capital Management LLC bought a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $66,000. Institutional investors own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 49,670 shares of the stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $241.01, for a total transaction of $11,970,966.70. Following the completion of the transaction, the chief executive officer owned 7,229 shares in the company, valued at $1,742,261.29. This trade represents a 87.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Nick Pizzie sold 33,000 shares of Axsome Therapeutics stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the transaction, the chief financial officer owned 42,867 shares of the company’s stock, valued at $10,291,938.03. The trade was a 43.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 200,766 shares of company stock worth $46,685,646 over the last 90 days. 20.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on AXSM. Piper Sandler reaffirmed an “overweight” rating and issued a $258.00 target price on shares of Axsome Therapeutics in a report on Monday, May 4th. Robert W. Baird boosted their price objective on Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Royal Bank Of Canada reduced their price objective on Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. UBS Group reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Monday. Finally, Truist Financial upgraded Axsome Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.60.

Axsome Therapeutics Trading Up 0.8%

Shares of AXSM stock opened at $207.15 on Thursday. The company has a 50 day moving average of $229.34 and a 200-day moving average of $206.61. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. Axsome Therapeutics, Inc. has a 12-month low of $112.90 and a 12-month high of $260.19. The firm has a market cap of $10.85 billion, a P/E ratio of -55.24 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). The firm had revenue of $218.38 million during the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. Sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.8 earnings per share for the current year.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
• Neutral Sentiment: The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
• Neutral Sentiment: A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
• Negative Sentiment: The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.